Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Reversal Alert: VTIX, MARA, IBRX, BATL, NDRA, EEIQ Gain Momentum as Multi-Sector Catalysts Build
Via AB Newswire
News headline image
Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations
NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). 
Via TheNewswire.com
News headline image
Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations
NEW YORK, NY - March 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). 
Via TheNewswire.com
News headline image
Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets ↗
On March 24, 2026, choppy, oil-driven trading and fresh AI disruption fears pressured major U.S. indexes. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
Most active stocks in Tuesday's session ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Down More Than 20% Today ↗
Perhaps the company's management will be more careful after a third regulatory run-in. 
Via The Motley Fool
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
ImmunityBio Crashes On FDA Warning Over Anktiva Claims ↗
ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions. 
Via Benzinga
News headline image
Why ImmunityBio Stock Is Up More Than 11% Today ↗
The young biopharma outfit's growth potential continues to expand. 
Via The Motley Fool
News headline image
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
From ImmunityBio, Inc.
Via Business Wire
News headline image
Stocks Under $10: IBRX, VTIX, NDRA, SMX – 2026 Watch Now!
Via AB Newswire
News headline image
Why Did IBRX Stock Jump 7% In Pre-Market Today? ↗
The NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA for more patients. This move broadens its potential use, though the indication is still not FDA-approved. 
Via Stocktwits
News headline image
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
From ImmunityBio, Inc.
Via Business Wire
News headline image
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗
Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement. 
Via Stocktwits
Topics ETFs
News headline image
IBRX Stock Rises 3% Pre-Market: ImmunityBio Reports Breakthrough In NK Cell Therapy Production ↗
ImmunityBio also completed a Phase 1 study combining its memory cytokine-enhanced NK cell therapy with ANKTIVA. 
Via Stocktwits
News headline image
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
From ImmunityBio, Inc.
Via Business Wire
News headline image
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact ↗
The company expects global expansion to drive “substantial” revenue starting in 2027. 
Via Stocktwits
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
Via MarketBeat
News headline image
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst ↗
The project relies on an AI-driven manufacturing robot, Leonardo, to automate production and potentially scale NK cell output. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease. 
Via Stocktwits
News headline image
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews ↗
The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva. 
Via Stocktwits
News headline image
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva ↗
Investors are focused on Anktiva’s next regulatory step, as ImmunityBio seeks to expand the therapy to BCG-unresponsive papillary bladder cancer. 
Via Stocktwits
News headline image
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗
Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility. 
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases. 
Via Stocktwits
News headline image
IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗
Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and kept an ‘Overweight’ rating on the shares. 
Via Stocktwits
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.